Tourmaline Bio to Present at Upcoming Investor Conferences

TRML 10.31.2024

SERA-AI Powered Highlights
Drug:TOUR006 pacibekitug
Date of Upcoming Event:2024-11-07
Name of Upcoming Event:Truist Securities BioPharma Symposium, New York Panel: Close to Heart: Innovative Approaches to Targeting Cardiac & Skeletal Muscle Illnesses
Date of Upcoming Event:2024-11-12
Name of Upcoming Event:Guggenheim Securities Healthcare Innovation Conference, Boston Fireside Chat
Full Press ReleaseSEC FilingsOur TRML Tweets

About Gravity Analytica

Recent News

  • 01.10.2025 - Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
  • 12.10.2024 - Investor Day
  • 12.10.2024 - Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day

Recent Filings

  • 12.10.2024 - EX-99.1 EX-99.1
  • 12.10.2024 - 8-K Current report

NEW YORK,Oct. 31, 2024(GLOBE NEWSWIRE) --Tourmaline Bio, Inc.(Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conferences:

Truist Securities BioPharma Symposium,New YorkPanel:Close to Heart: Innovative Approaches to Targeting Cardiac & Skeletal Muscle IllnessesThursday, November 7, 2024 at 2:35 pm ET

Guggenheim Securities Healthcare Innovation Conference,BostonFireside ChatTuesday, November 12, 2024 at 1:30 pm ET

Live webcasts and replays, when available, will be available under "Events and Presentations" in the News & Investors section of theTourmaline Biowebsite atir.tourmalinebio.com.

For more information aboutTourmaline Bioand pacibekitug, please visithttps://www.tourmalinebio.comor follow us onLinkedInorX.

AboutTourmaline BioTourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006).

Media ContactScient PRSarah MishekSMishek@ScientPR.com

Investor ContactMeru AdvisorsLee M. Sternlstern@meruadvisors.com

Primary Logo

Source: Tourmaline Bio, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com